Profile data is unavailable for this security.
About the company
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
- Revenue in EUR (TTM)1.33m
- Net income in EUR-23.49m
- Incorporated2004
- Employees51.00
- LocationPhaxiam Therapeutics SA60 avenue RockefellerLYON 69008FranceFRA
- Phone+33 478744438
- Fax+33 478755629
- Websitehttps://erytech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acticor Biotech SA | 0.00 | -18.65m | 13.45m | 24.00 | -- | 28.63 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Ikonisys SA | 538.56k | -2.40m | 15.57m | 11.00 | -- | 0.8521 | -- | 28.92 | -0.2499 | -0.2499 | 0.056 | 1.75 | 0.0246 | 1.14 | 6.20 | 48,960.00 | -10.94 | -- | -12.55 | -- | 2.72 | -- | -444.76 | -- | 0.0818 | -36.79 | 0.1007 | -- | 68.94 | -- | -328.57 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 2.34m | -849.00k | 16.32m | 56.00 | -- | 2.21 | -- | 6.98 | -0.7853 | -0.7853 | 2.15 | 6.70 | 0.1368 | 0.9869 | 2.87 | 41,767.86 | -4.91 | -3.18 | -7.20 | -4.04 | 22.83 | 98.91 | -35.87 | -27.90 | 0.8691 | -16.73 | 0.4472 | -- | 1.48 | 23.72 | 25.13 | -- | 3.57 | -- |
| Valerio Therapeutics SA | 1.80m | -20.34m | 16.39m | 19.00 | -- | 1.10 | -- | 9.11 | -0.1566 | -0.1566 | 0.0133 | 0.0961 | 0.0459 | -- | 1.07 | 94,736.84 | -51.92 | -34.19 | -67.72 | -40.59 | 70.39 | 84.11 | -1,130.22 | -586.99 | -- | -171.66 | 0.3776 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
| SMAIO SA | 7.62m | 1.06m | 17.88m | 37.00 | 16.79 | 1.65 | 7.51 | 2.35 | 0.2038 | 0.2038 | 1.46 | 2.07 | 0.5624 | 0.1871 | 17.23 | 206,027.60 | 7.81 | -7.87 | 10.24 | -19.76 | 96.95 | 96.04 | 13.89 | -22.48 | 2.54 | 11.07 | 0.1991 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 18.53m | 51.00 | -- | 0.7234 | -- | 13.97 | -5.56 | -5.56 | 0.3139 | 4.22 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| NicOx SA | 3.57m | -17.36m | 18.74m | 11.00 | -- | 0.4081 | -- | 5.24 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 22.23m | 3.00 | -- | 5.59 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 22.65m | 22.00 | -- | 5.61 | -- | 21.12 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Predilife SA | 317.79k | -4.22m | 25.86m | 19.00 | -- | -- | -- | 81.36 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
Data as of May 24 2024. Currency figures normalised to Phaxiam Therapeutics SA's reporting currency: Euro EUR
3.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2022 | 162.91k | 2.68% |
| OFI Invest Asset Management SAas of 29 Feb 2024 | 16.89k | 0.28% |
| BVF Partners LPas of 28 Mar 2023 | 9.73k | 0.16% |
| Generali Asset Management SGR SpAas of 30 Dec 2022 | 7.00k | 0.12% |
| Friedland Gestion SASas of 26 Jan 2024 | 3.38k | 0.06% |
| BBVA Asset Management SA SGIICas of 31 Dec 2023 | 2.50k | 0.04% |
| Deka Investment GmbHas of 31 Dec 2023 | 870.00 | 0.01% |
| Montaigne Capital SASas of 29 Feb 2024 | 450.00 | 0.01% |
| Soci�t� G�n�rale Gestion SAas of 29 Feb 2024 | 0.00 | 0.00% |
| Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2018 - 30 Apr 2024Source: FactSet Research Systems Inc.
